Novo Nordisk registered a new Phase 1 cagrilintide tolerability study aimed at GLP-1-RA-intolerant obesity patients — the day's most material signal; Pfizer's MET233 obesity Phase 1 also flipped to COMPLETED. — 2 trials with material updates.

Competitive Intelligence · Obesity and Type 2 Diabetes

Wednesday, May 27, 2026

Novo Nordisk registered a new Phase 1 cagrilintide tolerability study aimed at GLP-1-RA-intolerant obesity patients — the day's most material signal; Pfizer's MET233 obesity Phase 1 also flipped to COMPLETED.

Key Signals · 2 trials updated

  • NEW REGISTRATION — Novo Nordisk posted a Phase 1 cagrilintide study (NCT07607587), genuine first-in-registry posting in-window (StudyFirstPostDate 2026-05-26): a 114-pt, US-only, double-blind feasibility trial testing tolerability of the amylin analog in obesity patients who discontinued GLP-1-RAs due to GI adverse events.
  • STATUS TRANSITION — Pfizer's Phase 1 obesity study of MET233 (NCT07022977, n=144) flipped to COMPLETED (PCD/SCD 2026-04-21, posted 2026-05-26); clean completion, no results yet (hasResults=false).
  • FOLLOW-UP (non-material) — Pfizer's berobenatide Phase 3 VESPER-6 (NCT07595549, already reported 2026-05-19/20) updated only its estimated study start (2026-06-02 → 2026-06-30); PCD/SCD unchanged — minor amendment, not counted.
  • SCOPE HYGIENE — propose adding MET233 (Metsera/Pfizer amylin analog 'MET-233i') to tracked_molecules; the list currently tracks only MET097.
  • NOISE — several in-scope sponsor trials (Roche enicepatide P3 pair, Lilly orforglipron adolescent P3, Hanmi HM15275 P2, Lilly bimagrumab+tirzepatide P2) showed LastUpdatePostDate bumps in-window with no identifiable material delta (no first-posting, status, PCD/SCD, or enrollment change) — treated as administrative.

Material signals — window 2026-05-26 → 2026-05-27

Four query passes were run against AREA[LastUpdatePostDate]RANGE[2026-05-26,2026-05-27]: (1) condition class obesity/T2D at Phase 2/3; (2) priority sponsors (Novo, Lilly, Pfizer) any phase via condition. Coverage is contiguous with the prior run (2026-05-25 covered through 2026-05-25). Each in-window hit was classified by what actually changed (StudyFirstPostDate vs status / PCD / SCD / enrollment), not by first-sighting.

1. Novo Nordisk — Phase 1 cagrilintide tolerability study — NEW REGISTRATION ★

NCT07607587 · NN9833-8420 · StudyFirstPostDate 2026-05-26 (genuine first registry posting, in-window) · NOT_YET_RECRUITING

  • What changed: first-in-registry posting (StudyFirstSubmit 2026-05-19 → Post 2026-05-26). Qualifies under priority-sponsor / any-phase rule; cagrilintide is a tracked molecule.
  • Design: Phase 1, randomized, quadruple-blind, parallel-group feasibility study. Cagrilintide vs matching placebo, both SC, 26-week dosing; n=114 (est.).
  • Population / thesis: adults BMI ≥30 with a documented history of discontinuing GLP-1-RA therapy due to GI adverse events, judged unsuitable for GLP-1-RA re-initiation; excludes T2D/diabetes and recent weight-management or glucose-lowering drugs. Primary outcome = % of participants reaching standard-or-higher cagrilintide dose at Week 26.
  • Read: positions the amylin analog cagrilintide as a tolerability rescue / alternative for the large GLP-1-intolerant obesity population — a differentiated, non-incretin angle distinct from Novo's CagriSema program. The narrow feasibility design (dose-escalation tolerability, not weight efficacy) signals early de-risking of monotherapy in this subgroup.
  • Geography: 11 US sites (CA, FL ×4, NC ×2, SC, TN, TX ×2). US-only — within geographies_of_interest. Est. start 2026-05-29; PCD/SCD 2027-11-19.

2. Pfizer — Phase 1 MET233 in obesity/overweight — STATUS TRANSITION → COMPLETED

NCT07022977 · PHASE1 · n=144 · LastUpdatePostDate 2026-05-26

  • What changed: OverallStatus → COMPLETED; PCD = SCD = 2026-04-21 (≈5 weeks before the update), StatusVerified 2026-05. No WhyStopped (not a termination); hasResults = false (no results section yet).
  • Asset: MET233 = Metsera's amylin analog 'MET-233i', now a Pfizer asset post-acquisition. Completes a 144-pt early-phase obesity study; watch for a results posting or readout disclosure.
  • Note: MET233 is not in tracked_molecules (only MET097 is) — see Scope hygiene below. Captured here via the Pfizer priority-sponsor / any-phase pass.

3. Pfizer — Phase 3 berobenatide VESPER-6 — FOLLOW-UP, non-material

NCT07595549 · PHASE3 · n=954 · StudyFirstPostDate 2026-05-19 (NOT in-window) · LastUpdatePostDate 2026-05-27

  • Already reported as a new registration on 2026-05-19 and 2026-05-20. Not a new posting today.
  • What changed today: LastUpdateSubmit 2026-05-26 — estimated study start moved 2026-06-02 → 2026-06-30 (~4-week slip). PrimaryCompletionDate (2028-05-04) and StudyCompletionDate (2028-06-21), arms, endpoints, and enrollment are unchanged.
  • Classification: minor amendment with no PCD/SCD movement → administrative; not counted in trials_updated. Logged for continuity.

Update bumps with no identifiable material delta (treated as NOISE)

These in-scope sponsor trials had a 2026-05-26 LastUpdatePostDate but no first-posting, status, PCD/SCD, or enrollment change detectable from triage fields — consistent with administrative updates (contact/site text, annual re-verification):

  • NCT07351058 & NCT07351045 — Roche enicepatide (RO7795068) Phase 3 pair (obesity+T2D / obesity-only; n=1600 / 2000), RECRUITING, first posted 2026-01-20.
  • NCT06672939 — Lilly orforglipron Phase 3 in adolescents, RECRUITING, first posted 2024-11-04.
  • NCT07527650 — Hanmi HM15275 (triple agonist) Phase 2 in T2DM, RECRUITING, first posted 2026-04-14.
  • NCT06643728 — Lilly bimagrumab + tirzepatide Phase 2, ACTIVE_NOT_RECRUITING (PCD 2026-01-16 already passed; no results).
  • Out-of-scope by sponsor/molecule, excluded: NCT06935838 (U. Hawaii tirzepatide/HIV), NCT07469800 (Innovent IBI362/mazdutide — tracked molecule but non-tracked sponsor, not new, no delta), NCT06867718 (Regor RGT001-075 → COMPLETED), NCT05713799 (NIDDK), NCT07284511 (McGill tirzepatide/T1D), NCT04298203 (U. Minnesota phentermine), NCT05313802 & NCT04426474 (Lilly orforglipron Phase 1s completed 2022/2021 — old, admin re-verification).

If a same-day history diff confirms geographic site additions on the Roche enicepatide pivotals (a tracked geographic signal) or PCD movement on any of the above, those would promote to material in a subsequent run.

Scope hygiene — proposed Scope-block addition

  • Add MET233 (a.k.a. MET-233i) to tracked_molecules. Surfaced via NCT07022977 as a Pfizer/Metsera amylin analog completing a Phase 1 obesity study; the watchlist currently tracks the sibling MET097 only. Adding it preserves the audit trail rather than silently widening future queries.

Generated by Claude Code + ClinicalTrials.gov MCP · clinicaltrials.gov
Rendered: 2026-05-27T13:25:14.510Z · prompt f8ca428e6d80